Free Stock & ETF Comparisons

Compare EPR Properties and VICI Properties by experiential retail vs gaming venue coverage ratios, tenant diversification, AFFO yield, coverage ratio, and long-term specialty REIT value.

Compare Global Medical REIT and Alexandria Real Estate Equities by medical office vs life science campus tenant quality, occupancy, lease term length, dividend coverage, and risk profile.

Compare CTO Realty Growth and Simon Property Group by open-air convenience vs luxury retail format, cap rate, geographic concentration, dividend yield, and risk profile for income investors.

Compare ELME Communities and Essex Property Trust by DC metro vs California/Pacific Northwest apartment market, same-store NOI growth, supply risk, and dividend yield.

Compare NexPoint Residential Trust and Apartment Income REIT by value-add renovation capex program vs Class A stabilized rent, sunbelt exposure, leverage ratio, and total return potential.

Compare Plymouth Industrial REIT and Rexford Industrial Realty by infill vs secondary market industrial exposure, same-store NOI rent roll-up potential, occupancy, and dividend yield.

Compare Americold Realty Trust and Prologis by cold chain warehouse occupancy recovery, food supply chain tailwind vs e-commerce logistics rent growth, and AFFO yield.

Compare AMD and NVIDIA by AI inference performance per watt, MI300X hyperscaler adoption vs H200 market lock-in, open software ecosystem challenge, gross margin gap, and analyst upside.

Compare Oracle and Amazon by OCI AI infrastructure growth vs AWS dominance, database licensing renewal tailwinds, enterprise migration incentives, and which cloud stock wins the enterprise AI workload race.

Compare Microsoft and Meta Platforms by enterprise AI monetisation pace, Copilot vs Llama open-source approach, AI infrastructure spend, and which Big Tech company extracts more AI revenue.

Compare Palantir and ServiceNow by AIP AI monetisation, Now Assist AI adoption, government vs commercial AI contract depth, operating margin trajectory, and which enterprise AI platform is better valued.

Compare C3.ai and Palantir by revenue growth trajectory, AI platform adoption, US government contract depth, path to profitability, and which enterprise AI software stock offers better risk-reward.

Compare UiPath and Asana by RPA platform ARR, AI-driven workflow automation, enterprise deal upsell, net revenue retention, path to profitability, and competitive positioning against Microsoft.

Compare Monday.com and ServiceNow by SMB vs enterprise workflow platform, AI automation attach rate, net revenue retention, operating leverage, and which workflow software stock has more upside.

Compare HubSpot and Salesforce by AI marketing hub revenue, Agentforce enterprise deployment, SMB vs enterprise customer acquisition cost, and which CRM platform compounds better through 2026–2030.

Compare Freshworks and Salesforce by SMB customer service automation, Freddy AI product features, enterprise deal conversion, ARR growth, gross margin, and valuation.

Compare Zuora and Bill.com by recurring revenue billing automation, subscription metrics intelligence, SMB AP/AR automation revenue, and which financial workflow SaaS is better positioned.

Compare FedEx and Amazon by last-mile delivery network threat, business parcel yield, B2B industrial shipping revenue, margin improvement trajectory, and long-term delivery market positioning.

Compare XPO and Saia by network expansion from Yellow bankruptcy, pricing discipline, shipment volume momentum, margin profile, and which less-than-truckload carrier is better managed.

Compare CSX and Norfolk Southern by operating ratio improvement, intermodal volume trend, coal revenue decline rate, precision scheduled railroading maturity, and relative valuation.

Compare Union Pacific and CSX by network geography (western vs eastern US), intermodal competitive dynamics, bulk commodity exposure, dividend growth, and long-term ROIC.

Compare Triton International and WESCO International by global container fleet utilisation, data center electrical equipment demand, recurring revenue visibility, dividend, and valuation.

Compare Canadian Pacific Kansas City and Canadian National by CPKC's new Mexico–US–Canada trade corridor, CN's intermodal strength, revenue ton-mile growth, and which Canadian railway is the better ADR.

Compare Uber and Instacart by delivery category diversification, ad monetisation revenue per order, Uber Eats vs grocery delivery gross profit, and which delivery platform is the better investment.

Compare Trex Company and Masco Corporation by housing renovation cycle exposure, composite decking vs plumbing/cabinets segment, pricing power, gross margin, and long-term home improvement demand.

Compare Parker Hannifin and Emerson Electric by industrial automation software revenue, motion and control systems backlog, Meggitt aerospace integration, and long-term dividend compounder value.

Compare Rockwell Automation and Siemens AG by programmable logic controller market share, digital factory software revenue, AI-enhanced process control, and which automation ADR wins long-term.

Compare HDFC Bank and ICICI Bank by retail vs corporate lending mix, digital banking adoption, NIM trajectory, India consumer credit TAM, and which Indian bank ADR offers better growth-at-reasonable-price.

Compare Infosys and Wipro by revenue growth, AI consulting deal wins, US financial services client exposure, deal pipeline, operating margin, and which Indian IT giant is the better ADR.

Compare Tata Consultancy Services and Infosys by headcount efficiency, AI/GenAI transformation deal value, vertical mix, margin stability, and which premium Indian IT stock offers more long-term value.

Compare Sea Limited and MercadoLibre by total addressable market, Shopee vs Mercado e-commerce market share, Sea Money vs Mercado Pago fintech revenue, and profitability convergence.

Compare Grab Holdings and GoTo Group by GMV growth in ride-hailing and delivery, fintech AUM, path to adjusted EBITDA breakeven, and which SE Asian super-app is the better speculative bet.

Compare KraneShares CSI China Internet ETF and iShares MSCI China ETF by sector concentration, regulatory risk exposure, Alibaba/Tencent weighting, and which China ETF provides better risk-adjusted exposure.

Compare iShares MSCI India ETF and WisdomTree India Earnings Fund by large-cap vs earnings-weighted methodology, expense ratio, India demographic tailwind, and long-term return potential.

Compare iShares MSCI Brazil ETF and Vanguard FTSE Emerging Markets ETF by Brazil commodity cycle leverage, China concentration risk in VWO, political risk, and total return history.

Compare Grab Holdings' publicly traded investment thesis vs Gojek's (GoTo Group) strategy in Indonesia by market share in key verticals, fintech monetisation, and path to profitability.

Compare TD Bank and Royal Bank of Canada by US consumer banking presence, capital markets revenue, AML regulatory overhang (TD), dividend yield, and which Big Five Canadian bank is the safer ADR.

Compare Moderna and Recursion Pharmaceuticals by mRNA oncology pipeline vs AI-driven drug discovery platform, clinical-stage pipeline diversity, cash runway, and which next-generation biotech platform creates more long-term value.

Compare Regeneron and Vertex Pharmaceuticals by Eylea/Dupixent commercial durability, Trikafta CFTR sales, R&D pipeline depth, and which large-cap biotech has more durable long-term earnings power.

Compare Biogen and Gilead Sciences by Leqembi Alzheimer's commercial ramp, Biktarvy HIV franchise durability, oncology cell therapy pipeline, and which mid-to-large biotech offers better risk-adjusted upside.

Compare Alnylam and Ionis Pharmaceuticals by siRNA platform royalty stack, antisense oligonucleotide licensing revenue, Inclisiran commercial growth, and which nucleic acid medicine platform is better positioned.

Compare CRISPR Therapeutics and Editas Medicine by exa-cel sickle cell commercial launch, CRISPR delivery modality, patent position, cash runway, and which gene editing stock is the better speculation.

Compare Intellia Therapeutics and CRISPR Therapeutics by in-vivo liver delivery vs ex-vivo stem cell editing, transthyretin amyloidosis program, cash position, and clinical milestone catalysts.

Compare Exact Sciences and GoodRx by Cologuard screening revenue growth, GoodRx pharmacy network monetisation, gross margin trajectory, and which healthcare tech platform is the better recovery story.

Compare ACM Research and Onto Innovation by China revenue exposure, advanced packaging and inspection TAM, semiconductor equipment cycle positioning, and which small-cap equipment stock has more upside.

Compare Halozyme Therapeutics and ACADIA Pharmaceuticals by ENHANZE royalty stream growth, Daybue Rett syndrome commercial launch, pipeline risk, and which specialty pharma has more predictable revenue.

Compare Gilead Sciences and Merck by Biktarvy HIV franchise durability, Keytruda immuno-oncology patent cliff risk, HIV prevention lenacapavir launch, HPV vaccine market share, and which large pharma is better valued.

Compare Enphase Energy and SolarEdge Technologies by residential solar market share, battery storage attach rate, Europe headwind, gross margin compression, and which solar inverter company recovers fastest.